Manipulating the metabolism to improve the efficacy of CAR T-cell immunotherapy
Zitieren Sie bitte immer diese URN: urn:nbn:de:bvb:20-opus-220140
- The adoptive transfer of the chimeric antigen receptor (CAR) expressing T-cells has produced unprecedented successful results in the treatment of B-cell malignancies. However, the use of this technology in other malignancies remains less effective. In the setting of solid neoplasms, CAR T-cell metabolic fitness needs to be optimal to reach the tumor and execute their cytolytic function in an environment often hostile. It is now well established that both tumor and T cell metabolisms play critical roles in controlling the immune response byThe adoptive transfer of the chimeric antigen receptor (CAR) expressing T-cells has produced unprecedented successful results in the treatment of B-cell malignancies. However, the use of this technology in other malignancies remains less effective. In the setting of solid neoplasms, CAR T-cell metabolic fitness needs to be optimal to reach the tumor and execute their cytolytic function in an environment often hostile. It is now well established that both tumor and T cell metabolisms play critical roles in controlling the immune response by conditioning the tumor microenvironment and the fate and activity of the T cells. In this review, after a brief description of the tumoral and T cell metabolic reprogramming, we summarize the latest advances and new strategies that have been developed to improve the metabolic fitness and efficacy of CAR T-cell products.…
Autor(en): | Marsha Pellegrino, Francesca Del Bufalo, Biagio De Angelis, Concetta Quintarelli, Ignazio Caruana, Emmanuel de Billy |
---|---|
URN: | urn:nbn:de:bvb:20-opus-220140 |
Dokumentart: | Artikel / Aufsatz in einer Zeitschrift |
Institute der Universität: | Medizinische Fakultät / Kinderklinik und Poliklinik |
Sprache der Veröffentlichung: | Englisch |
Titel des übergeordneten Werkes / der Zeitschrift (Englisch): | Cells |
ISSN: | 2073-4409 |
Erscheinungsjahr: | 2020 |
Band / Jahrgang: | 10 |
Heft / Ausgabe: | 1 |
Aufsatznummer: | 14 |
Originalveröffentlichung / Quelle: | Cells (2021) 10:1, 14. https://doi.org/10.3390/cells10010014 |
DOI: | https://doi.org/10.3390/cells10010014 |
Allgemeine fachliche Zuordnung (DDC-Klassifikation): | 6 Technik, Medizin, angewandte Wissenschaften / 61 Medizin und Gesundheit / 610 Medizin und Gesundheit |
Freie Schlagwort(e): | Chimeric Antigen Receptor T cells; cancer; combined therapy; immunotherapy; metabolic reprogramming |
Datum der Freischaltung: | 10.08.2022 |
Datum der Erstveröffentlichung: | 24.12.2020 |
Lizenz (Deutsch): | CC BY: Creative-Commons-Lizenz: Namensnennung 4.0 International |